Ipca Labs to buy 33 percent stake in Unichem Labs for 1,034 crore
These transactions are subject to approval of the Competition Commission of India under the Competition Act, 2002 and such other approvals as may be required.
Mumbai: lpca Laboratories Limited has announced that the company has entered into a definitive Share Purchase Agreement (SPA) for acquisition of 2,35,01,440 fully paid-up equity shares of Rs. 2/- each, constituting 33.38% of the paid up equity share capital of M/s. Unichem Laboratories Ltd, from one of its promoter shareholder at a price @ Rs. 440/- per equity share aggregating to Rs. 1034.06 Crores.
The company is also making an open offer to the public equity shareholders of Unichem to acquire from them upto 26% of the fully diluted outstanding equity share capital at a price@ Rs. 440/- per share, under the relevant provisions of SEBI (Substantial Acquisition of shares and Takeovers) Regulations, 2011.
These transactions are subject to approval of the Competition Commission of India under the Competition Act, 2002 and such other approvals as may be required.
The business and product range of lpca and that of Unichem complements each others business and product range.
Premchand Godha, Promoter and Executive Chairman, lpca Laboratories said, "Unichem has developed an excellent and proven quality track record with a differentiated capability which is highly complementary to lpca's strengths. This acquisition is in line with our stated strategy to enhance our portfolio in our chosen growth markets. We both are well positioned to successfully integrate our product offerings and grow our businesses."
Dr. Prakash A. Mody, Promoter and Chairman and Managing Director, Unichem Laboratories said, "We are very excited about this transaction and believe that lpca is an ideal partner to take business of Unichem through its next phase of growth. For Unichem, employees and customers have been core to its business and I strongly believe, they will benefit from lpca's expertise in providing competitive and integrated services globally."
Mr. Jayendra Shah, Partner, N A Shah Advisors LLP acted as Advisor to Dr. Prakash A. Mody and Unichem Laboratories Ltd.
Read also: Unichem Labs bags USFDA nod for chronic angina drug Ranolazine Extended Release
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.